Development of botulinum toxin therapy

Dermatologic Clinics

Volumn 22, Issue 2, 2004, Pages 131-133

  Scott, Alan B ^a  

^a SMITH KETTLEWELL EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN;

BLEPHAROSPASM; DRUG SAFETY; DRUG TARGETING; ESTHETIC SURGERY; HUMAN; LEG CRAMP; PRIORITY JOURNAL; SHORT SURVEY; STRABISMUS; TORTICOLLIS;

EID: 2442451254     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(03)00019-6     Document Type: Review

References (7)

1. Smith Louis DS, Thomas Charles C. Botulism. Springfield (IL): Charles C. Thomas; 1977.
2. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology 1999;53:1850-3.
3. Drachman DB. Neuropoisons. In: Simpson LL, editor. New York: Plenum Press; 1971. p. 315-39.
4. Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985;12(4):314-6.
5. Drobik C, Laskawi R. Frey-Syndrom: Behandlung mit Botulinum-Toxin. HNO Aktuell 1994;2:142-4.
6. Dressler D, Benecke R. Initial experiences with clinical use of botulinum toxin type B. Nervenarzt 2002;73(2):194-8.
7. Kumar R, Seeberger L. Long-term safety, efficacy, and dosing of botulinum toxin B (Myobloc) in cervical dystonia (CD) and other movement disorders. Mov Disord 2002;17(Suppl 5):S292-3.